Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia

25 Apr 2015

Abstract excerpt

PURPOSE: In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate samples do not express 5α-reductase type 2 secondary to epigenetic modifications. We evaluated whether 5α-reductase type 2 expression in benign prostatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Diagnosis and Treatment
Share to Sexual function and dysfunction studies
Share to Urinary Bladder and Prostate Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25916673
DOI: 10.1016/j.juro.2015.04.079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic HyperplasiaPMID 25916673Read ↗

DNA Methyl Transferase 1 Reduces Expression of SRD5A2 in the Aging Adult ProstateSemantic proximity Read ↗

Integrative genomic, transcriptomic, and epigenomic analyses of benign prostatic hyperplasia reveal new options for therapySemantic proximity Read ↗

Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarraysSemantic proximity Read ↗

Epidemiological investigation of sex hormones and their metabolism-related gene single nucleotide polymorphisms in patients with benign prostatic hyperplasia complicated with late-onset hypogonadism: a retrospective cohort studySemantic proximity Read ↗

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.Semantic proximity Read ↗

Targeting phenotypic heterogeneity in benign prostatic hyperplasia.Semantic proximity Read ↗

CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.Semantic proximity Read ↗

A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study.Semantic proximity Read ↗

Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysisSemantic proximity Read ↗

DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasiaSemantic proximity Read ↗

Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSASemantic proximity Read ↗

Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.